Ebola vaccine: first large-scale trial begins in West Africa
Liberia has received the first batch, but experts warn it may be difficult to establish its efficacy

The first large-scale trial of an experimental Ebola vaccine is to begin today in one of the West African countries worst affected by the disease, following a successful preliminary safety trial.
The batch of vaccines, developed by the British pharmaceutical giant GlaxoSmithKline, was transported under tight security to an unknown location in Liberia, the BBC reports. Up to 30,000 volunteers in the country are expected to be involved in the trial, with a third receiving the vaccine.
The vaccine contains a small amount of the virus which scientists hope will trigger an immune response that will protect against infection.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Stephen Kennedy, the senior Liberian scientist involved in the trials said that the vaccine posed no risk to volunteers. "It is a weak strain and it cannot and will not cause Ebola, so it is impossible that any one of the volunteers will contact Ebola from the vaccine," he said.
GlaxoSmithKline's global vaccines chief Dr Moncef Slaoui described the shipment as "a major achievement", which "shows that we remain on track" with accelerated development of the Ebola vaccine.
"The initial phase one data... are encouraging and give us confidence to progress to the next phases of clinical testing, which will involve the vaccination of thousands of volunteers, including frontline healthcare workers," he said.
The company stressed, however, that the vaccine was still in its development phase and its long-term safety and efficacy would have to be established before it could be used on a wider scale.
"Any potential future use in mass vaccination campaigns will depend on whether the World Health Organization (WHO) regulators and other stakeholders are satisfied... and how quickly large quantities... can be made," said Slaoui.
Last month, the WHO said that the outbreak in West Africa had reached a turning point, as the number of new infections continued to decline, but warned against complacency in the fight to eradicate the disease entirely.
Paradoxically, this encouraging news may have a negative impact on the vaccine trial. "Because case numbers are starting to come down, it will become harder and harder to show if the vaccine is having any impact," Professor Jonathan Ball, a virus expert based at Nottingham University, told the BBC.
There is currently no proven vaccine or cure for Ebola and the unprecedented scale of the outbreak prompted governments, pharmaceutical companies and international health organisations to fast track the development of safe and effective treatments.
There are several other promising vaccines and treatments currently in development, with reports that the experimental drug zMapp, which was given to several Western healthcare workers who later recovered, will be trialled in the coming weeks.
The deadliest Ebola outbreak in history has so far claimed at least 8,641 lives and almost 22,000 people have been confirmed infected, although that number is expected to be much higher in reality.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
-
Delivery drivers face continuing heat danger with Trump's OSHA pick
The Explainer David Keeling is the former head of UPS and also worked at Amazon
-
Is that the buzzing sound of climate change worsening sleep apnea?
Under the radar Catching diseases, not those ever-essential Zzs
-
Codeword: July 3, 2025
The Week's daily codeword puzzle
-
One year after mass protests, why are Kenyans taking to the streets again?
today's big question More than 60 protesters died during demonstrations in 2024
-
What happens if tensions between India and Pakistan boil over?
TODAY'S BIG QUESTION As the two nuclear-armed neighbors rattle their sabers in the wake of a terrorist attack on the contested Kashmir region, experts worry that the worst might be yet to come
-
Why Russia removed the Taliban's terrorist designation
The Explainer Russia had designated the Taliban as a terrorist group over 20 years ago
-
Inside the Israel-Turkey geopolitical dance across Syria
THE EXPLAINER As Syria struggles in the wake of the Assad regime's collapse, its neighbors are carefully coordinating to avoid potential military confrontations
-
'Like a sound from hell': Serbia and sonic weapons
The Explainer Half a million people sign petition alleging Serbian police used an illegal 'sound cannon' to disrupt anti-government protests
-
The arrest of the Philippines' former president leaves the country's drug war in disarray
In the Spotlight Rodrigo Duterte was arrested by the ICC earlier this month
-
Ukrainian election: who could replace Zelenskyy?
The Explainer Donald Trump's 'dictator' jibe raises pressure on Ukraine to the polls while the country is under martial law
-
Why Serbian protesters set off smoke bombs in parliament
THE EXPLAINER Ongoing anti-corruption protests erupted into full view this week as Serbian protesters threw the country's legislature into chaos